Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency

Video

A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.

CN_GU_BTL_Seg05_Factors
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Subscribe Now!
      Recent Videos
      Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
      Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
      Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
      Outlining Risk Factor Identification and Mitigation in Bladder Cancer
      Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Perioperative Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
      Enfortumab Vedotin Combo Supersedes Other Advanced Bladder Cancer Options
      Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
      EV-302 Trial Shows ‘Impressive’ Data in Bladder Cancer Responder Population
      Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
      Managing AEs Associated With The EV-302 Trial Regimen in Bladder Cancer
      Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
      Enfortumab Vedotin Combo Yields ‘Transformative’ Urothelial Cancer Outcomes
      Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment
      Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment
      AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
      AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
      Related Content
      In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

      sBLAs Submitted for Nogapendekin Alfa Inbakicept in Lymphopenia/NMIBC

      Roman Fabbricatore
      April 16th 2025
      Article

      In quarter 1 of 2025, nogapendekin alfa inbakicept received regenerative medicine advanced therapy designation for lymphopenia.

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
      March 4th 2025
      Podcast

      The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

      FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

      FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

      Ariana Pelosci
      March 28th 2025
      Article

      Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

      Matthew Fowler;Jun Gong, MD
      March 15th 2022
      Podcast

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

      UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

      Tim Cortese
      March 11th 2025
      Article

      In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

      Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

      Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

      Tim Cortese
      March 4th 2025
      Article

      Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.